2-(QUINUCLIDIN-3-YL)PYRIDO[4,3-B]INDOL-1-ONES AND ISOQUINOLIN-1-ONES - POTENT CONFORMATIONALLY RESTRICTED 5-HT(3) RECEPTOR ANTAGONISTS

Several series of N-(quinuclidin-3-yl)aryl and heteroaryl-fused pyrido nes were synthesized and evaluated for 5-HT3 receptor affinity. In the heteroaryl series, inuclidin-3-yl)tetrahydropyrido-[4,3-b]indol-1-one (8a) and the 4,5-alkano-bridged analogues (14 and 15) displayed high 5-HT3 receptor affinity with pK(i) values > 9. The (3S)-quinuclidinyl isomers had > 10 fold higher affinity than the (3R)-isomers. In a seri es of 2-quinuclidin-3-yl)isoquinolin-1-ones, derivatives substituted w ith small lipophilic groups (25b-e) and with 4,5-alkano-bridges (34-36 ) also displayed high affinity. In particular, the hexahydro-1H-benz[d e]isoquinolinone (S,S)-37 was the highest affinity 5-HT3 receptor liga nd prepared (pK(i) 10.4). A number of the high affinity ligands were s hown to be potent 5-HT3 receptor antagonists in vivo as determined by inhibition of the B-J reflex in the anesthetized rat. Again, (S,S)-37 was the most active agent tested (ID50 0.02 mug/kg iv), and this compo und was also potent in blocking cisplatin-induced emesis in both the f erret and the dog. Computer modeling studies were performed, and previ ously reported 5-HT3 receptor antagonist pharmacophore models were ref ined to include a key lipophilic binding domain.